6550--Intent to Sole Source: Cepheid GeneXpert Infinity Molecular Reagents IDIQ
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically the Bay Pines VA Healthcare System, intends to procure Cepheid GeneXpert Infinity Molecular Reagents via a Fixed-Priced Single Award Indefinite Delivery Indefinite Quantity (IDIQ) contract. While initially intended as a sole source acquisition with Cepheid, the VA is issuing this notice to determine if competitive procurement is feasible. Offers are due February 20, 2026.
Scope of Work
This procurement is for an extensive range of infectious disease testing reagents compatible with the government-owned Cepheid GeneXpert Infinity systems. Required reagents cover microorganisms such as MRSA, C. difficile, CRE, CT/NG, Strep A, SARS-CoV-2, Influenza A/B, RSV, and Vaginal Infection Molecular Test. The goal is to ensure timely and accurate laboratory services for patient care, infection control, diagnosis, and antimicrobial stewardship.
Key requirements include:
- Procurement of specific, FDA-approved Cepheid GeneXpert® Infinity compatible reagents.
- Vendor must provide automatic shipment on standing orders or monthly, as well as "As Needed" or "Emergent Overnight" shipment capabilities.
- Vendor is responsible for all shipping costs.
- Reagents must be the most current FDA-approved versions.
- Information for meeting local discharge requirements for hazardous constituents.
Contract Details
- Contract Type: Fixed-Priced Single Award IDIQ
- Period of Performance: Ordering periods from April 1, 2026, through September 30, 2029 (3.5 years).
- Guaranteed Minimum Award: $100,000.00
- Maximum Aggregate Value: $3,500,000.00
- NAICS Code: 325413 (In-Vitro Diagnostic Substance Manufacturing)
- Size Standard: 1250 Employees
- Product Service Code: 6550
Submission & Evaluation
This notice is not a request for competitive proposals, but interested parties may submit a quotation, bid, or proposal with supporting evidence of their capability to meet the requirement. Responses will be considered solely to determine if a competitive procurement is warranted. If no responses are received, the government will proceed with the sole source acquisition. The government intends to evaluate offers and award without discussions.
- Offer Due Date: February 20, 2026, by 13:00 PM Eastern Standard Time.
- Submission: Email responses to Moneque Rodriguez at moneque.rodriguez@va.gov.
Set-Aside
The acquisition is unrestricted, despite the initial intent for a sole source procurement under FAR 12.102(b) and 41 USC §1901 due to the specialized nature of the reagents and compatibility with existing equipment. The government is seeking competitive proposals to assess market capability.
Additional Notes
An update to VA Handbook 6500.6, Appendix C, regarding VA Information and Information System Security/Privacy Language, is effective immediately and applies to contracts.